While various molecular targeting medications, including anti-tumor necrosis factor-α (TNF-α) antibody, have greatly improved therapeutic strategies for UC, these drugs may be associated with other problems, such as serious infections or loss of response [3]. This evidence concerns the gene TNF and infection.